• Sakshi Prasad, Maanya Rajasree Katta, Shuchi Abhishek, Rishala Sridhar, Sai Sudha Valisekka, Maha Hameed, Jasneet Kaur, and Namrata Walia.
• Faculty of Medicine, National Pirogov Memorial Medical University, 21018, Vinnytsya, Ukraine. Electronic address: sakshiprasad8@gmail.com.
• Dis Mon. 2023 May 1; 69 (5): 101441101441.

AbstractLewy Body Dementia is the second most frequent neurodegenerative illness proven to cause dementia, after Alzheimer's disease (AD). It is believed to be vastly underdiagnosed, as there is a significant disparity between the number of cases diagnosed clinically and those diagnosed via neuropathology at the time of postmortem autopsy. Strikingly, many of the pharmacologic treatments used to treat behavioral and cognitive symptoms in other forms of dementia exacerbate the symptoms of DLB. Therefore, it is critical to accurately diagnose DLB as these patients require a specific treatment approach. This article focuses on its pathophysiology, risk factors, differentials, and its diverse treatment modalities. In this study, an English language literature search was conducted on Medline, Cochrane, Embase, and Google Scholar till April 2022. The following search strings and Medical Subject Headings (MeSH) terms were used: "Lewy Body Dementia," "Dementia with Lewy bodies," and "Parkinson's Disease Dementia." We explored the literature on Lewy Body Dementia for its epidemiology, pathophysiology, the role of various genes and how they bring about the disease, biomarkers, its differential diagnoses and treatment options.Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

20 keywords...

hide…